Item request has been placed! ×
Item request cannot be made. ×
loading  Processing Request

SARS-CoV-2 vaccine induced humoral & cell-mediated immune responses in Indian cohort of rheumatoid arthritis.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read Online Read More Add to Saved list
  • Additional Information
    • Source:
      Publisher: Scientific Scholar Country of Publication: United States NLM ID: 0374701 Publication Model: Print Cited Medium: Internet ISSN: 0971-5916 (Print) Linking ISSN: 09715916 NLM ISO Abbreviation: Indian J Med Res Subsets: MEDLINE
    • Publication Information:
      Publication: 2024- : [Pittsford, NY] : Scientific Scholar
      Original Publication: New Delhi : Council Of Medical Research
    • Subject Terms:
      Arthritis, Rheumatoid*/immunology ; Arthritis, Rheumatoid*/virology ; COVID-19*/prevention & control ; COVID-19*/immunology ; COVID-19*/virology ; COVID-19 Vaccines*/immunology ; COVID-19 Vaccines*/administration & dosage ; SARS-CoV-2*/immunology ; Immunity, Cellular* ; Immunity, Humoral*; Humans ; Female ; Male ; Middle Aged ; India/epidemiology ; Adult ; Immunoglobulin G/blood ; Immunoglobulin G/immunology ; Antibodies, Viral/blood ; Antibodies, Viral/immunology ; Spike Glycoprotein, Coronavirus/immunology
    • Abstract:
      Background & objectives The COVID-19 pandemic came up with distinct challenges for patients with rheumatoid arthritis indicating higher risk of infection and severity due to SARS-CoV-2. In this study, we performed the immunotyping of humoral and cell-mediated responses in patients with rheumatoid arthritis to assess characteristics and durability of Covid vaccine-induced immune memory. Methods We enrolled 50 individuals with rheumatoid arthritis who had received SARS COV-2 vaccine (Covaxin/Covishield). Of these 26 were assessed within six months of the second vaccine dose (T1) and 24 were evaluated 6-9 months after the third dose (T2). Serum IgG titres were measured using chemiluminescent microparticle immunoassay (CLIA), and lymphocyte immunophenotyping. In vitro challenge with the SARS-CoV-2 spike protein was performed using flow cytometry. Results Patients vaccinated with Covishield showed significantly higher IgG titres and elevated levels of cytokines such as TNFα and IFNγ compared to those vaccinated with Covaxin. The Covishield group also exhibited a higher percentage of antigen-specific and inflammatory T cell subsets, contributing to the overall cytokine pool in patients with rheumatoid arthritis. In vitro stimulation with the SARS-CoV-2 spike protein further activated lymphocytes in Covishield-vaccinated individuals. Interpretation & conclusions Our study presents the increased effectiveness of Covishield in initiating responses compared to Covaxin. Covishield vaccinated patients with rheumatoid arthritis show higher antigen specificity and T cell activation indicating a shift of the immune system towards a Th1 phenotype, which makes it imperative to focus on development of safe and durable vaccines with a continuous follow up for the patients with rheumatoid arthritis to control disease severity.
    • References:
      J Physiol Biochem. 2013 Jun;69(2):335-47. (PMID: 23385669)
      Viral Immunol. 2020 May;33(4):294-306. (PMID: 32326852)
      Diabetes Metab Syndr. 2022 Feb;16(2):102424. (PMID: 35150961)
      Front Immunol. 2022 Sep 23;13:928501. (PMID: 36211366)
      Immunol Res. 2022 Jun;70(3):289-315. (PMID: 35192185)
      Cytokine. 2015 Dec;76(2):527-536. (PMID: 26321413)
      Immunity. 2020 Jul 14;53(1):19-25. (PMID: 32610079)
      Lancet Reg Health Southeast Asia. 2024 Feb 27;22:100361. (PMID: 38482152)
      Curr Opin Rheumatol. 2007 May;19(3):296-301. (PMID: 17414959)
      Tohoku J Exp Med. 2020;250(4):271-278. (PMID: 32321874)
      Biomed Pharmacother. 2018 Oct;106:1011-1023. (PMID: 30119166)
      Ann Rheum Dis. 2010 Sep;69(9):1580-8. (PMID: 20699241)
      Immunity. 2022 Dec 13;55(12):2255-2270. (PMID: 36516818)
      Vaccines (Basel). 2022 Nov 17;10(11):. (PMID: 36423038)
      Signal Transduct Target Ther. 2020 Aug 31;5(1):179. (PMID: 32868756)
      J Clin Virol. 2022 Oct;155:105269. (PMID: 36029637)
      Hum Vaccin Immunother. 2024 Dec 31;20(1):2410579. (PMID: 39434214)
      J Infect Dis. 2004 Feb 15;189(4):648-51. (PMID: 14767818)
      Arch Med Res. 2021 May;52(4):423-433. (PMID: 33541740)
      J Med Virol. 2021 Jan;93(1):250-256. (PMID: 32592501)
      NPJ Vaccines. 2021 Apr 21;6(1):60. (PMID: 33883557)
      Front Immunol. 2021 Mar 11;12:636768. (PMID: 33777028)
      Cells. 2021 Oct 23;10(11):. (PMID: 34831081)
      PLoS One. 2014 Jun 17;9(6):e100266. (PMID: 24936783)
      J Rheumatol. 2010 Aug 1;37(8):1596-606. (PMID: 20595277)
      Future Virol. 2021 Jun;:. (PMID: 34181704)
      Sci Rep. 2017 Apr 19;7(1):933. (PMID: 28424490)
      Curr Opin Rheumatol. 2018 Mar;30(2):207-214. (PMID: 29206659)
    • Contributed Indexing:
      Keywords: Activation induced marker; CD4+ T cells; CD8+ T cells; Covaxin; Covishield; rheumatoid arthritis
    • Accession Number:
      0 (COVID-19 Vaccines)
      0 (Immunoglobulin G)
      0 (Antibodies, Viral)
      0 (Spike Glycoprotein, Coronavirus)
      0 (spike protein, SARS-CoV-2)
    • Publication Date:
      Date Created: 20251227 Date Completed: 20251227 Latest Revision: 20251231
    • Publication Date:
      20251231
    • Accession Number:
      PMC12744542
    • Accession Number:
      10.25259/IJMR_1010_2025
    • Accession Number:
      41454813